Smoldering Multiple Myeloma (SMM) is an asymptomatic condition that acts as an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. First described by Kyle and Greipp in 1980, SMM typically affects individuals aged 50 to 70 and is usually diagnosed incidentally when an M protein is discovered during laboratory tests for various disorders.
What is High-Risk Smoldering Multiple Myeloma?
High-risk smoldering multiple myeloma (HRSMM) refers to SMM patients with a significantly higher likelihood of progressing to active multiple myeloma within two years. The progression risk ranges from 50-79% in the first two yea...
